Treatment of RA: MOA

Question 1

Tofacitinib

Answer 1

Janus kinase (JAK) (tyrosine kinases) inhibitors – decrease inflammation by modulating immune response (decrease IgG, IgM, IgA, CRP)

Question 2

Baricitinib

Answer 2

Janus kinase (JAK) (tyrosine kinases) inhibitors – decrease inflammation by modulating immune response (decrease IgG, IgM, IgA, CRP)

Question 3

Etanercept

Answer 3

Soluble tumor necrosis factor receptor; TNF-alpha inhibitors

Question 4

Infliximab

Answer 4

Bind to TNF-alpha with high affinity & specificity

Question 5

Adalimumab

Answer 5

Bind to TNF-alpha with high affinity & specificity

Question 6

Golimumab

Answer 6

Bind to TNF-alpha with high affinity & specificity

Question 7

Certolizumab pegol

Answer 7

Pegylated Fab fragment of humanized anti-TNF antibody; lacks Fc portion & avoids Fc-mediated effects such as complement or antibodydependent cell-mediated cytotoxicity

Question 8

Rituximab

Answer 8

Directed against B cell surface antigen CD20 – causes depletion of B cells (B cells contribute to inflammation)

Question 9

Abatacept

Answer 9

Selective costimulation modulator that inhibits Tlymphocyte activation

Question 10

Tocilizumab

Answer 10

IL-6 receptor-inhibiting monoclonal antibody

Question 11

Sarilumab

Answer 11

IL-6 receptor antagonist

Question 12

Anakinra

Answer 12

Interleukin-1 receptor antagonist